Dr. Matthew Robert Denny, MD

Dr. Denny practices at Pacific Vision Surgery Center LLC - HOPD in San Francisco, California.

Dr. Denny's NPI, 1619351467, was assigned on July 10, 2015. Dr. Denny graduated from Tulane School of Medicine in 2015. Dr. Denny holds California license A144010.

Dr. Denny's primary practice is Pacific Vision Surgery Center LLC - HOPD, at 711 Van Ness Ave, San Francisco, CA 94102.

Dr. Denny's primary practice is Pacific Vision Surgery Center LLC - HOPD in San Francisco, California. Dr. Denny is also affiliated with California Pacific Medical Center Van Ness Campus. Dmand AI also links Dr. Denny to 1 more hospital, 1 group practice or clinic, 1 ambulatory surgery center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Denny practices, 5 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Denny's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Denny is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Denny's licenses on file in 3 states: California, Kentucky and Ohio.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Denny treats.

CMS data shows 2,486 Medicare services from Dr. Denny across 19 procedure codes in 2024, for 844 Medicare patients. Medicare paid $258,198 for them.

CMS counts 844 Medicare patients who saw Dr. Denny in 2024. The largest group is 65 to 74, with 370 patients. 71% of them have high cholesterol, and 55% have high blood pressure. 7% are also on Medicaid. Their average risk score is 0.89, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Denny's median patient age at 71, with 52% women.

In 2024, Dr. Denny wrote 1,133 Medicare Part D claims for 319 patients. 44% of them were for generic drugs. CMS names the drug for 1,007 of them, across 18 drugs with 11 or more claims each, at $146,702 in total drug cost. In 2023, CMS named 892 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Denny for performance year 2024, reported as part of a group. Dr. Denny accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 211 procedures of cataract surgery by Dr. Denny, more than 84% of the clinicians it reports for that procedure.

Dmand AI links 12 papers to Dr. Denny, published from 2018 to 2023. 2020 was the busiest year, with 3. The most frequent topics are Stem Cell Transplantation, Corneal Diseases and Limbus Corneae. Dr. Denny has published most often in Cornea. Dr. Denny's most frequent co-authors are Amit Govil, MD, Joseph Hugh Jeffrey, MD and Khaliq H. Kurji, MD.

CMS Open Payments shows 164 general payments to Dr. Denny from 24 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 99% of the total. Alcon Laboratories Inc paid the most, $2,837.

Dr. Denny graduated from Tulane School of Medicine in 2015.

Dr. Denny is in network with 15 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.